Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Avrobio

Avrobio
2015 FOUNDED
PUBLIC STATUS
51-60 EMPLOYEES
AVRO STOCK SYMBOL
$15.58 SHARE PRICE (As of Friday Closing)
Description

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in the development of potentially curative ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose. The company manufactures products include AVR-RD-02, AVR-RD-03, and AVR-RD-04 which are used for various diseases such as Fabry, Gaucher, Pompe, and Cystinosis.

Website
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Primary Office
  • One Kendall Square
  • Building 300, Suite 201
  • Cambridge, MA 02139
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Avrobio’s full profile, request a free trial.

Avrobio Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$11.85 - $53.70 $376M $15.77 -$4.53 148K 24.1M

Avrobio Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 404,527 419,402
Revenue 0 0 0 0
EBITDA (56,898) (47,707) (18,660) (4,670)
Net Income (55,222) (46,361) (18,648) (4,664)
Total Assets 117,368 133,479 7,022 5,400
Total Debt 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Avrobio Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Avrobio‘s full profile, request access.

Request full access to PitchBook

Avrobio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Avrobio‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Avrobio Competitors (50)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom 000 00000 00000000000 00000
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
0000 00000000000 Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000000 00000000 Corporate Backed or Acquired Boston, MA 00 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Watertown, MA 00 00000 000000000 00000
To view this company’s complete list of competitors, request access »

Avrobio Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Avrobio‘s full profile, request access.

Request full access to PitchBook

Avrobio Executive Team (8)

Name Title Board
Seat
Contact
Info
Geoff MacKay Chief Executive Officer, President & Board Member
Katina Dorton JD Chief Financial Officer
Deanna Petersen Chief Business Officer
Jeffrey Medin Ph.D Co-Founder
Kim Warren Ph.D Head of Operations
You’re viewing 5 of 8 executives. Get the full list »

Avrobio Board Members (8)

Name Representing Role Since Contact
Info
Annalisa Jenkins Self Board Member 000 0000
Bruce Booth Ph.D Atlas Venture Chairman of the Board of Director 000 0000
Christopher Paige Ph.D Avrobio Co-Founder & Board Member 000 0000
Geoff MacKay Avrobio Chief Executive Officer, President & Board Member 000 0000
Ian Clark Avrobio Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »